Depression News

According to a recent poll conducted by the American Psychiatric Association, 75% of Americans said mental health support should be provided to incarcerated persons.

Antidepressants desvenlafaxine, paroxetine, venlafaxine and vortioxetine were found to have reasonable acceptability, efficacy and tolerability in the treatment of adults with stable major depressive disorder.

Risk for developing mental illness among North Korean refugees and immigrants living in South Korea was significantly higher than for those in the general population, according to a study published in JAMA Network Open.

HHS, through the Substance Abuse and Mental Health Services Administration, announced $109.4 million in funding from the Bipartisan Safer Communities Act for states and territories to improve mental health services.

The U.S. Surgeon General has issued a framework that outlines the foundational role employers should play in promoting mental health and well-being in the workplace.

Electroconvulsive therapy appeared to be superior to ketamine for improving depression severity in the acute phase, findings from a systematic review and meta-analysis published in JAMA Psychiatry showed.

Empyrean Neuroscience Inc. has announced its launch as a genetic engineering company dedicated to developing fungi- and plant-based therapeutics for the treatment of neuropsychiatric and neurologic disorders.

Animal therapy and technological interventions in long-term care facilities were shown to improve loneliness in older adults, a systematic review published in JAMA Network Open showed.

Arrivo BioVentures, a biopharmaceutical company, has announced preliminary results from a randomized, placebo-controlled phase 2 clinical trial of SP-624, a first-in-class, sirtuin 6 activator for the treatment of major depressive disorder.

Following its announcement of nearly $300 million in funding — $27 million specifically for youth — the Biden administration has announced an additional $15 million in funding for state-based mental health clinics.